Butterfly Biosciences

Executive Summary

Butterfly Biosciences is addressing the critical issue of gynecologic misdiagnosis by developing precision diagnostic tools that aim to reduce the time to accurate diagnosis from 4–6 months to significantly shorter periods. Leveraging advances in genetics, genomics, and synthetic biology, the company focuses on creating molecular assays and biomarkers for gynecologic pathologies. By modernizing the standard of care, Butterfly Biosciences has the potential to improve outcomes for women's health, reducing unnecessary procedures and enabling earlier intervention. Founded in 2021 and based in San Francisco, the company operates in a large and underserved market, though it remains in early stages with limited public information on funding or pipeline progress.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement70% success
• Q4 2026Initial Clinical Validation Data for Lead Diagnostic Test50% success
• Q3 2026Partnership with Major Women's Health Hospital Network40% success